Liu, Baorui

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

Ren, Z., Xu, J., Bai, Y., Xu, A., Cang, S., Du, C., Li, Q., Lu, Y., Chen, Y., Guo, Y., et al. (2021) · The Lancet Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 1,124

Targeting VEGF/VEGFR to modulate antitumor immunity

Yang, J., Yan, J., & Liu, B. (2018) · Frontiers in Immunology

Angiogenesis and VEGF in CancerCancer Immunotherapy and Biomarkers

Cited by 646

Successively activatable ultrasensitive probe for imaging tumour acidity and hypoxia

Zheng, X., Mao, H., Huo, D., Wu, W., Liu, B., & Jiang, X. (2017) · Nature Biomedical Engineering

Molecular Sensors and Ion DetectionNanoplatforms for cancer theranostics

Cited by 210

Engineered Bacteriophage-Based In Situ Vaccine Remodels a Tumor Microenvironment and Elicits Potent Antitumor Immunity

Lei, L., Yan, J., Xin, K., Li, L., Sun, Q., Wang, Y., Chen, T., Wu, S., Shao, J., Liu, B., et al. (2024) · ACS Nano

Immunotherapy and Immune ResponsesBacterial Cancer Therapy

Cited by 33